Answers are grounded in this paper and cite their sources.
The Food and Drug Administration (FDA) announced Aug. 3 approval of Janssen Pharmaceutical's supplemental new drug application (sNDA) for the expanded use of SPRAVATO esketamine Clll nasal spray for the treatment of major depressive disorder (MDD) with acute suicidal ideation or behavior. SPRAVATO was initially approved by the FDA March 5, 2019, for the treatment of treatment‐resistant depression.
No takes yet. Share an insight, caveat, or question.
Valerie A. Canady (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: